Moderna (NASDAQ:MRNA) Given New $108.00 Price Target at UBS Group

Moderna (NASDAQ:MRNA) had its price target trimmed by UBS Group from $140.00 to $108.00 in a report published on Thursday, Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other research firms have also weighed in on MRNA. JPMorgan Chase & Co. lowered Moderna from a “neutral” rating to an “underweight” rating and decreased their price target for the company from $88.00 to $70.00 in a research report on Friday, September 13th. Hsbc Global Res upgraded shares of Moderna from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 28th. Bank of America cut their price target on shares of Moderna from $130.00 to $110.00 and set a “neutral” rating on the stock in a report on Friday, September 13th. Deutsche Bank Aktiengesellschaft upgraded shares of Moderna from a “sell” rating to a “hold” rating and reduced their price target for the company from $85.00 to $80.00 in a research report on Wednesday, August 7th. Finally, Oppenheimer cut shares of Moderna from an “outperform” rating to a “market perform” rating in a research report on Friday, September 13th. Two analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Moderna presently has an average rating of “Hold” and an average target price of $94.65.

Moderna Stock Performance

Shares of NASDAQ MRNA traded up $0.58 during midday trading on Thursday, reaching $53.38. The company’s stock had a trading volume of 411,771 shares, compared to its average volume of 4,320,680. Moderna has a one year low of $52.26 and a one year high of $170.47. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. The company has a 50 day moving average price of $68.35 and a 200 day moving average price of $103.20.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.47) by $0.14. The company had revenue of $241.00 million for the quarter, compared to analysts’ expectations of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The firm’s revenue was down 29.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($3.62) earnings per share. Equities research analysts expect that Moderna will post -9.94 EPS for the current fiscal year.

Insider Buying and Selling at Moderna

In other news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the transaction, the chief financial officer now owns 9,505 shares in the company, valued at approximately $571,440.60. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO James M. Mock sold 715 shares of the company’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at approximately $571,440.60. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the transaction, the chief financial officer now owns 8,600 shares in the company, valued at approximately $682,754. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 18,184 shares of company stock worth $2,037,931 over the last ninety days. 15.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Moderna

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vontobel Holding Ltd. raised its position in shares of Moderna by 148.2% in the third quarter. Vontobel Holding Ltd. now owns 116,088 shares of the company’s stock valued at $7,758,000 after purchasing an additional 69,313 shares during the period. Profund Advisors LLC grew its stake in Moderna by 20.9% in the 2nd quarter. Profund Advisors LLC now owns 56,218 shares of the company’s stock valued at $6,676,000 after buying an additional 9,719 shares during the last quarter. Tobam raised its holdings in Moderna by 121.6% in the 3rd quarter. Tobam now owns 27,794 shares of the company’s stock worth $1,857,000 after acquiring an additional 15,249 shares during the period. Swedbank AB lifted its position in Moderna by 149.6% during the 3rd quarter. Swedbank AB now owns 85,099 shares of the company’s stock worth $5,687,000 after acquiring an additional 51,000 shares during the last quarter. Finally, Marshall Wace LLP boosted its holdings in Moderna by 295.5% during the second quarter. Marshall Wace LLP now owns 35,200 shares of the company’s stock valued at $4,180,000 after acquiring an additional 26,300 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.